The DOI matches its Crossref record; 99 of the 100 references it cites were found in a registry or an index.
Progress and challenges in translating the biology of atherosclerosis
Abstract
Atherosclerosis is a chronic disease of the arterial wall, and a leading cause of death and loss of productive life years worldwide. Research into the disease has led to many compelling hypotheses about the pathophysiology of atherosclerotic lesion formation and of complications such as myocardial infarction and stroke. Yet, despite these advances, we still lack definitive evidence to show that processes such as lipoprotein oxidation, inflammation and immunity have a crucial involvement in human atherosclerosis. Experimental atherosclerosis in animals furnishes an important research tool, but extrapolation to humans requires care. Understanding how to combine experimental and clinical science will provide further insight into atherosclerosis and could lead to new clinical applications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These symptoms are thought to further exacerbate inflammation and, in doing so, contribute to the pathogenesis of various diseases of aging (6–8), many of which involve excessive cytokine activity (9, 10).”
From Clustering of depression and inflammation in adolescents previously exposed to childhood adversity (2012) · cites this paper as [10]
In the citing paper
“Atherosclerosis originates from damaged endothelium that allows the accumulation of cholesterol-containing LDL particles in the arterial wall that tend to be oxidized, which triggers an inflammatory response that fails to resolve”
From Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty (2018) · cites this paper as [144]
In the citing paper
“These limitations are among the reasons that have motivated several groups to issue recommendations for accelerating the translation of nanoparticles into the clinic158,161,162.”
From Perspectives and opportunities for nanomedicine in the management of atherosclerosis (2011) · cites this paper as [162]
Citations
Cites
1 retracted
Toll-Like Receptor 2 Mediates Apolipoprotein CIII–Induced Monocyte Activation: Retracted
Kawakami, A., Osaka, M., Aikawa, M., Uematsu, S., Akira, S., Libby, P., Shimokado, K., Sacks, F. M., & Yoshida, M. (2008) · Circulation Research · doi:10.1161/circresaha.108.178426 · Cited by 76
Self-citationRetractedInflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Self-citationEffects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Self-citationIntensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Lusis, A. J. (2000) · Nature · doi:10.1038/35025203 · Cited by 4,880
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881 · cited 1×
“Clinical trials of one agent with PPAR-α-stimulating activity, gemfibrozil, have shown a reduction in cardiovascular event”
BackgroundRosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Self-citationSequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Glass, C. K., & Witztum, J. L. (2001) · Cell · doi:10.1016/s0092-8674(01)00238-0 · Cited by 3,094
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 1×
“Another agent with relatively weak PPAR-α-agonist action, fenofibrate, has not reduced events in several large clinical trial”
BackgroundC-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
Self-citationThe immune response in atherosclerosis: a double-edged sword
Hansson, G. K., & Libby, P. (2006) · Nature reviews. Immunology · doi:10.1038/nri1882 · Cited by 2,220
Self-citationNissen, S. E., Nicholls, S. J., Sipahi, I., Libby, P., Raichlen, J. S., Ballantyne, C. M., Davignon, J., Erbel, R., Fruchart, J. C., Tardif, J.-C., et al. (2006) · JAMA · doi:10.1001/jama.295.13.jpc60002 · Cited by 2,047
Self-citationNiemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G. G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,818
Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa060900 · Cited by 1,729
Nissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Tabas, I., Williams, K. J., & Borén, J. (2007) · Circulation · doi:10.1161/circulationaha.106.676890 · Cited by 1,399
Epidoxorubicin In, A., Cascinu, S., Labianca, R., Barone, C., Santoro, O., Carnaghi, C., Frontini, L., Aitini, E., Rota, S., Torri, V., et al. (2009) · Springer eBooks · doi:10.1007/978-0-387-78665-0_6514 · Cited by 1,394
Kathiresan, S., Melander, O., Guiducci, C., Surti, A., Burtt, N. P., Rieder, M. J., Cooper, G. M., Roos, C., Voight, B. F., Havulinna, A. S., et al. (2008) · Nature Genetics · doi:10.1038/ng.75 · Cited by 1,386
Goldstein, J. L., & Brown, M. S. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.179564 · Cited by 1,344
Jonasson, L., Holm, J., Skalli, O., Bondjers, G., & Hansson, G. K. (1986) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.6.2.131 · Cited by 1,329
Self-citationBouhlel, M. A., Derudas, B., Rigamonti, E., Dièvart, R., Brozek, J., Haulon, S., Zawadzki, C., Jude, B., Torpier, G., Marx, N., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.06.010 · Cited by 1,325
Tacke, F., Alvarez, D., Kaplan, T. J., Jakubzick, C., Spanbroek, R., Llodra, J., Garin, A., Liu, J., Mack, M., van Rooijen, N., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28549 · Cited by 1,323
Świrski, F. K., Libby, P., Aïkawa, E., Alcaide, P., Luscinskas, F. W., Weissleder, R., & Pittet, M. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29950 · Cited by 1,308
Self-citation(2005) · JAMA · doi:10.1001/jama.293.11.1338 · Cited by 1,209 · cited 1×
“Well-powered randomized clinical trials have consistently shown that antioxidant vitamins, such as vitamins E and C, do not reduce cardiovascular events over the timescale and doses studie”
MethodNatural regulatory T cells control the development of atherosclerosis in mice
Ait‐Oufella, H., Salomon, B. L., Potteaux, S., Robertson, A.-K. L., Gourdy, P., Zoll, J., Merval, R., Esposito, B., Cohen, J. L., Fisson, S., et al. (2006) · Nature Medicine · doi:10.1038/nm1343 · Cited by 1,126
Self-citationMacrophage death and defective inflammation resolution in atherosclerosis
Tabas, I. (2010) · Nature Reviews Immunology · doi:10.1038/nri2675 · Cited by 1,120
Rajamäki, K., Lappalainen, J., Öörni, K., Välimäki, E., Matikainen, S., Kovanen, P. T., & Eklund, K. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011765 · Cited by 1,039
Großer, T. (2005) · Journal of Clinical Investigation · doi:10.1172/jci27291 · Cited by 1,031
Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60447-5 · Cited by 1,010
Self-citationVaisar, T., Pennathur, S., Green, P. S., Gharib, S. A., Hoofnagle, A. N., Cheung, M. C., Byun, J., Vuletic, S., Kassim, S., Singh, P., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci26206 · Cited by 942 · cited 1×
“HDL particles associate with dozens of proteins, many with biological activities that have relevance to atherogenesi”
BackgroundSelf-citationEffects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., Grobbee, D. E., Cass, A., Chalmers, J., & Perkovic, V. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60656-3 · Cited by 927
Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events
Robins, S. J., Collins, D. E., Wittes, J. T., Papademetriou, V., DEEDWANIA, P. C., Schaefer, E. J., McNamara, J. R., Kashyap, M. L., Hershman, J. M., WEXLER, L. F., et al. (2001) · JAMA · doi:10.1001/jama.285.12.1585 · Cited by 917
Endothelial Dysfunction, Hemodynamic Forces, and Atherogenesisa
Gimbrone, M. A., Topper, J. N., Nagel, T., Anderson, K. R., & García‐Cardeña, G. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06318.x · Cited by 855
Safety of anacetrapib in patients with or at high risk for coronary heart disease
Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009744 · Cited by 749
Tran, D. Q., Ramsey, H. E., & Shevach, E. M. (2007) · Blood · doi:10.1182/blood-2007-06-094656 · Cited by 738
Developmental Basis of Vascular Smooth Muscle Diversity
Majesky, M. W. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.141069 · Cited by 729
Tardif, J. (2007) · JAMA · doi:10.1001/jama.297.15.jpc70004 · Cited by 725
Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2
Parmar, K. M. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24787 · Cited by 710
(d)-β-Hydroxybutyrate Inhibits Adipocyte Lipolysis via the Nicotinic Acid Receptor PUMA-G
Taggart, A. K. P., Kero, J. T., Gan, X., Cai, T., Cheng, K., Ippolito, M. C., Ren, N., Kaplan, R. A., Wu, K., Wu, T.-J., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500213200 · Cited by 675
9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response
Harismendy, O., Notani, D., Song, X., Rahim, N. G., Tanasă, B., Heintzman, N. D., Ren, B., Fu, X., Topol, E. J., Rosenfeld, M. G., et al. (2011) · Nature · doi:10.1038/nature09753 · Cited by 619
Pleiotropic effects of statin therapy: molecular mechanisms and clinical results
Wang, C., Liu, P., & Liao, J. K. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.11.004 · Cited by 599
Palinski, W., Miller, E. R., & Witztum, J. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.3.821 · Cited by 591
Modulation of atherosclerosis in mice by Toll-like receptor 2
Mullick, A. E. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25482 · Cited by 549
Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice
Caligiuri, G., Nicoletti, A., Poirier, B., & Hansson, G. K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci7272 · Cited by 544
Self-citationHDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis
Tall, A. R., Yvan-Charvet, L., Terasaka, N., Pagler, T., & Wang, N. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.03.001 · Cited by 540
Serruys, P. W. J. C., García‐García, H. M., Buszman, P. E., Erné, P., Verheye, S., Aschermann, M., Duckers, H., Bleie, Ø., Dudek, D., Bøtker, H. E., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.771899 · Cited by 498
Is the Oxidative Modification Hypothesis Relevant to Human Atherosclerosis?
Steinberg, D. H., & Witztum, J. L. (2002) · Circulation · doi:10.1161/01.cir.0000014762.06201.06 · Cited by 473
B cell depletion reduces the development of atherosclerosis in mice
Ait‐Oufella, H., Herbin, O., Bouaziz, J., Binder, C. J., Uyttenhove, C., Laurans, L., Taleb, S., Vré, E. A. V., Esposito, B., Vilar, J., et al. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20100155 · Cited by 469
Oxidized Low-Density Lipoprotein and Atherosclerosis
Steinberg, D. H., & Witztum, J. L. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.179697 · Cited by 460
The LDL modification hypothesis of atherogenesis: an update
Steinberg, D. H. (2008) · Journal of Lipid Research · doi:10.1194/jlr.r800087-jlr200 · Cited by 452
Disruption of TGF-β signaling in T cells accelerates atherosclerosis
Robertson, A.-K. L., Rudling, M. J., Zhou, X., Gorelik, L., Flavell, R. A., & Hansson, G. K. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18607 · Cited by 440
Self-citationLoss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis
Taleb, S., Romain, M., Ramkhelawon, B., Uyttenhove, C., Pasterkamp, G., Herbin, O., Esposito, B., Pérez, N., Yasukawa, H., Snick, J. V., et al. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090545 · Cited by 426
The role of oxidized phospholipids in atherosclerosis
Berliner, J. A., Leitinger, N., & Tsimikas, S. (2008) · Journal of Lipid Research · doi:10.1194/jlr.r800074-jlr200 · Cited by 404
Libby, P. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.07.006 · Cited by 388
Self-citationSchunkert, H., Götz, A., Braund, P. S., McGinnis, R. E., Trégouët, D., Mangino, M., Linsel‐Nitschke, P., Cambien, F., Hengstenberg, C., Stark, K. J., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.730614 · Cited by 388
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin
Jones, P. H., & Davidson, M. H. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.08.076 · Cited by 387
Vascular biology of atherosclerosis: overview and state of the art
Libby, P. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)03143-0 · Cited by 362
Self-citationAssociation between a literature-based genetic risk score and cardiovascular events in women
Paynter, N. P. (2010) · JAMA · doi:10.1001/jama.2010.119 · Cited by 361
The metabolism and anti-atherogenic properties of HDL
Rye, K.-A., Bursill, C. A., Lambert, G., Tabet, F., & Barter, P. J. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800034-jlr200 · Cited by 331
Arginase-1 and Ym1 are markers for murine, but not human, alternatively activated myeloid cells
Raes, G., Van den Bergh, R., De Baetselier, P., & Ghassabeh, G. H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.6561 · Cited by 302
Chapman, M. J., Le Goff, W., Guerin, M., & Kontush, A. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp399 · Cited by 298
Adaptive immunity and atherosclerosis
Andersson, J., Libby, P., & Hansson, G. K. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.07.002 · Cited by 295
Self-citationMorgan, T. M., Krumholz, H. M., Lifton, R. P., & Spertus, J. A. (2007) · JAMA · doi:10.1001/jama.297.14.1551 · Cited by 270
Ridker, P. M. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03404.x · Cited by 269
Self-citationMaron, R., Sukhova, G. K., Faria, A. M. C., Hoffmann, E. C., Mach, F., Libby, P., & Weiner, H. L. (2002) · Circulation · doi:10.1161/01.cir.0000029750.99462.30 · Cited by 267
Self-citationInhibition of T cell response to native low-density lipoprotein reduces atherosclerosis
Hermansson, A., Ketelhuth, D. F. J., Strodthoff, D., Wurm, M., Hansson, E. M., Nicoletti, A., Paulsson‐Berne, G., & Hansson, G. K. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20092243 · Cited by 239
Self-citationA Role for Oxidized Phospholipids in Atherosclerosis
Berliner, J. A., & Watson, A. D. (2005) · New England Journal of Medicine · doi:10.1056/nejmp058118 · Cited by 229
Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux
Asztalos, B. F., de la Llera-Moya, M., Dallal, G. E., Horvath, K. V., Schaefer, E. J., & Rothblat, G. H. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500187-jlr200 · Cited by 224
Madhur, M. S., Funt, S. A., Li, L., Vinh, A., Chen, W., Lob, H. E., Iwakura, Y., Blinder, Y., Rahman, A. M., Quyyumi, A. A., et al. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.227629 · Cited by 212
Inflammation and Atherothrombosis
Libby, P., & Ridker, P. M. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.08.011 · Cited by 204
Self-citationLowering LDL—not only how low, but how long?
Brown, M. S., & Goldstein, J. L. (2006) · Science · doi:10.1126/science.1125884 · Cited by 204
Tardif, J., McMurray, J. J. V., Klug, E., Small, R., Schumi, J., Choi, J., Cooper, J., Scott, R. C., Lewis, E. F., L’Allier, P. L., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60763-1 · Cited by 204
Eriksson, P., Nilsson, L., Karpe, F., & Hamsten, A. (1998) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.18.1.20 · Cited by 187
Update on strategies to increase HDL quantity and function
Duffy, D., & Rader, D. J. (2009) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.94 · Cited by 172
Barter, P. J., & Kastelein, J. J. P. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.09.042 · Cited by 171
Heart Attacks: Gone with the Century?
Brown, M. S., & Goldstein, J. L. (1996) · Science · doi:10.1126/science.272.5262.629 · Cited by 163
Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice
van Es, T., van Puijvelde, G. H. M., Ramos, O. H., Segers, F. M., Joosten, L. A. B., van den Berg, W. B., Michon, I. M., de Vos, P., van Berkel, T. J. C., & Kuiper, J. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.07.152 · Cited by 163
Atherosclerotic lesions in mouse and man: is it the same disease?
Bentzon, J. F., & Falk, E. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833ded6a · Cited by 147
The role of innate immunity in atherogenesis
Hartvigsen, K., Chou, M.-Y., Hansen, L. F., Shaw, P. X., Tsimikas, S., Binder, C. J., & Witztum, J. L. (2008) · Journal of Lipid Research · doi:10.1194/jlr.r800100-jlr200 · Cited by 143
Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis
Libby, P. (2008) · Journal of Lipid Research · doi:10.1194/jlr.r800099-jlr200 · Cited by 137
Self-citationHDL Remodeling During the Acute Phase Response
Jahangiri, A., de Beer, M. C., Noffsinger, V. P., Tannock, L. R., Ramaiah, C., Webb, N. R., van der Westhuyzen, D. R., & de Beer, F. C. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.178681 · Cited by 135
The Vascular Biology of Atherosclerosis and Imaging Targets
Libby, P., DiCarli, M. F., & Weissleder, R. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.069633 · Cited by 134
Self-citationBrewer, H. B. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000121505.88326.d2 · Cited by 126
Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk
Brown, B. G., & Zhao, X.-Q. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.039 · Cited by 84
Siscovick (2003) · doi:10.1161/01.cir.0000074779.11379.62 · Cited by 81
Vaccination against atherosclerosis? Induction of atheroprotective immunity
Hansson, G. K., & Nilsson, J. Å. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0151-x · Cited by 73
Self-citationInhibition of IL-17A in atherosclerosis
Cheng, X. C., Taleb, S., Wang, J., Tang, T., Chen, J., Gao, X., Yao, R., Xie, J.-J., Yu, X., Xia, N., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.12.034 · Cited by 71
Interleukin-17: friend or foe in atherosclerosis?
Taleb, S., Tedgui, A., & Mallat, Z. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833dc7f9 · Cited by 65
Steinberg, D. I. (2007) · Thammasat University Digital Collections · Cited by 45
Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosis.
Navab, M., Anantharamaiah, G. M., Reddy, S. T., Lenten, B. J. V., Hough, G., Wagner, A. C., Nakamura, K., Garber, D. W., Datta, G., Segrest, J. P., et al. (2003) · PubMed · Cited by 35
National Institutes of Health Center for Human Immunology Conference, September 2009
Nussenblatt, R. B., Bielekova, B., Childs, R. W., Krensky, A. M., Strober, W., & Trinchieri, G. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05682.x · Cited by 14
Fibrates in CVD: a step towards personalised medicine
Staels, B. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60758-1 · Cited by 14
Flagged first, then by citations
1 of the 100 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
NF-κB signaling in inflammation
Liu, T., Zhang, L., Joo, D., & Sun, S.-C. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.23 · Cited by 8,791
Macrophage biology in development, homeostasis and disease
Wynn, T. A., Chawla, A., & Pollard, J. W. (2013) · Nature · doi:10.1038/nature12034 · Cited by 4,684
Inflammation in Atherosclerosis
Libby, P. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.179705 · Cited by 3,796
Self-citationInflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty
Ferrucci, L., & Fabbri, E. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0064-2 · Cited by 3,690
Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis
Gimbrone, M. A., & García‐Cardeña, G. (2016) · Circulation Research · doi:10.1161/circresaha.115.306301 · Cited by 3,694
Metadata
- Authors
- Libby, P., Ridker, P. M., & Hansson, G. K.
- Affiliations
- Brigham and Women's Hospital (US)
- Karolinska University Hospital (SE)
- Corresponding author
- Libby, Peter
- Venue
- Nature
- Published
- 2011-05
- Volume
- 473
- Issue
- 7347
- Pages
- 317-325
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2033896075
- Semantic Scholar
- 31a83a618339a5f25357342f3633f5a423880eb6
- Cited by
- 4,010
- References
- 100
- Citations by year
- 2026: 169 · 2025: 235 · 2024: 252 · 2023: 249 · 2022: 283 · 2021: 342 · 2020: 299 · 2019: 264 · 2018: 271 · 2017: 304 · 2016: 271 · 2015: 286 · 2014: 258 · 2013: 232 · 2012: 230
- FWCI
- 22.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- atherosclerosis, atherosclerotic plaque formation, lipoprotein oxidation, inflammation, immunity, animal models, animal-to-human extrapolation, myocardial infarction, stroke, translational research
- MeSH terms
- Animals, Humans, Inflammation, Cholesterol, HDL, Cholesterol, LDL, Triglycerides, Atherosclerosis, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
